Alexander "Bo" Cumbo is the President and CEO of Solid Biosciences Inc., a biotech firm focused on advancing treatments for Duchenne muscular dystrophy. He joined the company in late 2022, bringing a wealth of experience from various leadership roles in...

Alexander "Bo" Cumbo is the President and CEO of Solid Biosciences Inc., a biotech firm focused on advancing treatments for Duchenne muscular dystrophy. He joined the company in late 2022, bringing a wealth of experience from various leadership roles in the biotech sector, including positions at Sarepta Therapeutics and Vertex Pharmaceuticals. A graduate of Auburn University with a degree in Laboratory Technology, Cumbo has spent nearly two decades in the industry, focusing on commercial strategies and product development. His insider trading history shows significant investments in Solid Biosciences, including sales peaking at over $8 million in mid-2020, indicating a strong personal stake in the company’s success. In 2023, Cumbo received a total compensation of $775,000, which highlights a performance-driven pay structure consistent with biotech industry norms. Also noteworthy is his commitment to shareowner alignment, as seen in his stock options and rewards tied to company performance. Cumbo also serves on the board of Verve Therapeutics, adding another layer to his leadership profile in the healthcare space.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Solid Biosciences Inc. CEOs

S

Alexander (Bo) Cumbo

CEO of Solid Biosciences Inc.

Education

Bachelor of Science in Laboratory Technology from Auburn University.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1971 - 54 years ago

CEO of Solid Biosciences Inc. for

2 years 6 months (Nov 2022 - Present)

Previous Experience

President and Chief Executive Officer at AavantiBio; held positions at Sarepta Therapeutics, Vertex Pharmaceuticals, and Gilead Sciences.

Rivals

Competitors/colleagues of Alexander (Bo) Cumbo

Holdings

See how much did Alexander (Bo) Cumbo make over time.

As CEO of Solid Biosciences Inc., Alexander Cumbo holds a substantial stake in the company, showcasing his confidence in its future. His insider trading records reveal fluctuations in stock sales, notably peaking at $8.09 million in July 2020 before settling...

As CEO of Solid Biosciences Inc., Alexander Cumbo holds a substantial stake in the company, showcasing his confidence in its future. His insider trading records reveal fluctuations in stock sales, notably peaking at $8.09 million in July 2020 before settling lower in recent months. His wealth in company holdings has varied, with notable sales reflecting a mix of strategy and market timing. For instance, in 2023 alone, his stocks were valued at around $6.79 million in June before dropping to $4.32 million by November, showing his active engagement with the company’s performance. These shifts illustrate Cumbo's keen awareness of market dynamics while maintaining a substantial interest in Solid Biosciences through his vested stock awards, which were worth approximately $200,000 in 2023. This engagement underscores both his personal commitment and financial tie to the company’s direction and success.

Mar 18, 2025

S

shares

SLDB @ $4.93

S

shares

SRPT @ $73.54

Total Stock Sold

$12.54M

SRPT

$12.54M

96,700 SRPT shares

What if they kept their stock?

If Alexander (Bo) Cumbo didn't sell their stock, today they would have:
Extra SRPT96,700 shares worth $14.31M.
This is 14.09% and $1.77M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Alexander (Bo) Cumbo.

SRPT

6,700 shares

SRPT

Feb 28, 2020

Received

SRPT

$5.27M

SRPT at $125.50/share

Dec 13, 2019

Sale

SRPT

4,876 shares

SRPT

Mar 28, 2019

Received

SRPT

$2.10M

SRPT at $140.00/share

Feb 1, 2019

Sale

SRPT

$4.64M

SRPT at $137.32/share

Jul 9, 2018

Sale

SRPT

$242.64K

SRPT at $41.00/share

Jul 20, 2017

Sale

Compensation History

See how much did Alexander (Bo) Cumbo make over time.

In 2023, Alexander (Bo) Cumbo’s total compensation was $775,000, and it consisted of a base salary of $450,000, a bonus of $75,000 tied to performance metrics, and vested stock worth about $200,000. Previous years indicate a spike in his earnings, particularly in 2022 when he earned about $2.5 million, primarily driven by a large volume of vested restricted stock units. This reflects a trend in biotech that rewards executives based on the company's performance achievements. Cumbo's bonuses and equity awards are closely linked to Solid Biosciences’ operational milestones and revenue growth, aligning his incentives with those of shareholders and emphasizing the importance of performance in his role. His approach to compensation highlights a structured yet competitive pay philosophy designed to engage leadership in long-term company growth.

Year

2023

Total Compensation

$775.00K

Salary

$450.00K

Board Justification

The compensation philosophy is designed to align the CEO's interests with those of shareholders, focusing on performance-based incentives and competitive benchmarking against peers.

Bonus

$75.00K

Board Justification

The bonus is based on the achievement of specific performance metrics set by the Board of Directors for the fiscal year 2023.

Other

$50.00K

Board Justification

Other compensation includes health benefits, retirement contributions, and other perquisites provided to the CEO.

Restricted Stock

$200.00K(10K Common Stock)

Board Justification

The stock that vested in 2023 is part of the long-term incentive plan, which vests based on continued employment and performance metrics over a three-year period.

Performance Metrics

Performance metrics include revenue growth, operational milestones, and strategic objectives set forth by the Board.

Other Solid Biosciences Inc. CEOs

Here are other CEOs of Solid Biosciences Inc.

Ilan Ganot

Founder and Ex-CEO of Solid Biosciences Inc.

June 2018 - December 2022